Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add filters








Language
Year range
1.
Article in English | IMSEAR | ID: sea-172796

ABSTRACT

Chronic kidney disease (CKD) is a global public health issue demanding continuous improvement in its management. Different international groups and organizations have now achieved a good progress in its definition, classification (staging), treatment and referral criteria to nephrologists. In definition of CKD, "CKD is defined as abnormalities of kidney structure or function, present for at least three months with implications for health", the phrase "with implications for health" has been added at the end of the previous definition, which reflects the concept that there may be certain abnormalities of kidney structure or function that do not have prognostic consequences (for example, a simple renal cyst). At staging of CKD, grade 3 has been subdivided into G3a and G3b, according to whether the glomerular filtration rate (GFR) is (59 - 45) or (44 - 30) ml/min/1.73m2, respectively. Furthermore, albuminuria has been classified in any GFR grade, in to A1, A2 or A3 according to the albumin-creatinine ratio (ACR) in an isolated urine sample for values <3, 3-30 or >30mg/mmol, respectively. The term "microalbuminuria" has now been replaced by the term "moderately increased albuminuria". For GFR measurement Chronic Kidney Disease Epidemiology Collaboration (CKD- EPI) equation has been preferred than the Modification of Diet in Renal Disease (MDRD) study equation and new 2012 KDIGO guidelines consider the use of alternative formulas to be acceptable if they have been shown to improve accuracy when compared with the CKD-EPI formula. For detection of albuminuria ACR is preferred rather than conventional 24 hours urine albumin. The recommended BP control target is <_140/90mmHg (both diabetic and non-diabetic) if ACR <3mg/mmol and a stricter target is suggested, with BP <_130/80mmHg, (both in diabetic and non-diabetic) if the ACR is >_ 3mg/mmol. Use of erythropoisis-stimulating agent (ESA) in anemia of CKD should be rational; to avoid its adverse effects like stroke, thrombosis or hypertension acceleration and hemoglobin goals should not exceed 11 g per dl. Treating dyslipidaemia in CKD with statins for all adults >50 years of age, irrespective of low density lipoprotien (LDL) cholesterol levels is recommended. Referral to nephrologist should be rational according to guidelines and at least one year prior to the start of renal replacement therapy (RRT).

2.
3.
Article in English | IMSEAR | ID: sea-172775

ABSTRACT

Aspirin is the widely used cheap antiplatelet agent globally. Since marketing it was unbeaten for use in coronary diseases and ischemic stroke patients. Unfortunately for the last two decades the term ''Aspirin resistance'' (AR) has been evolved due to it's failure to protect the aspirin users against major cardiovascular events. Although the PlA1/A2 polymorphism in the GPIIIa platelet receptor along with other factors have been identified as responsible for this resistance, the term has not yet been defined. There is no consensus about ideal platelet function test. So it is more appropriate to say "treatment failure" to aspirin therapy rather using the term AR. Although Clopidogrel is being used alone or in combination with aspirin to overcome AR,platelet receptor (p2y12) inhibitors both Prasugrel and Ticagrelor are more potent than Clopidogrel in Acute Coronary Syndrome (ACS). Worldwide Prasugrel and Ticagrelor have been included in different guidelines to use in ACS.

4.
Article in English | IMSEAR | ID: sea-172679

ABSTRACT

Bronchial asthma is an atopic disease characterized by chronic airway inflammation and hyper-responsiveness. Severe acute asthma is a medical emergency and sometimes difficult to treat. This prospective study was done at Dhaka Medical College Hospital from January 1997 to January 1998. Total 30 patients of bronchial asthma were included in this study. Diagnosis was established on the basis of symptoms, evidence of airflow obstruction and its reversibility by bronchodilator therapy. The age range was 18 to 80 years with a mean 36.64±4.91. Of them, 63% were male and 37% were female. It revealed that all patients had classical triad of dyspnoea, wheeze and cough. Almost all patients (80%) had some precipitating agents for their attack. Regarding treatment of severe acute asthma - Nebulized salbutamol is superior to conventional intravenous aminophylline, as p value of nebulized salbutamol group is <0.001 which is significant. So, severe acute asthma should be managed with nebulized salbutamol instead of intravenous aminophylline.

5.
Article in English | IMSEAR | ID: sea-172644

ABSTRACT

Type 2 Diabetes Mellitus (T2DM) is a complex disease with the co-existence of several pathophysiological abnormalities. Both microvascular and macrovascular complications are the main causes of morbidity and mortality, which develops due to endothelial dysfunction. Upregulation of reactive oxygen species, chronic inflammatory and hypercoagulable states are the pathologic basis of vascular dysfunctions in T2DM. To overcome all these abnormalities, different classes of antihyperglycaemic agents have developed. Unfortunately none is able to show satisfactory glycaemic control and to modulate vascular dysfunction. Incretin hormones are secreted from intestine during meal, which enhance insulin secretion and inhibit glucagon secretion from the pancreas. The incretin effect is severely reduced or absent in T2DM. Incretin-based new antidiabetics, both Dipeptidyl Peptidase-4 (DPP-4) inhibitors (Saxagliptin, Sitagliptin, Vildagliptin) and Glucagon Like Peptide-1 (GLP-1) analogs (Exenatide) are now being used globally. They are almost equally effective as conventional antidiabetics like Sulphonylureas (SU), Metformin (MET), Thiazolidinediones (TZD) and insulin when given as monotherapy or combined with SU, MET or TZD as second line agent. Incretin-based agents do not cause hypoglycaemia, produce weight loss in spite of weight gain and do not retain salt or water and almost no gastrointestinal (GIT) symptoms. The agents correct vascular dysfunctions and dyslipidaemia and can be given in elderly and renal impaired patients.

6.
Article in English | IMSEAR | ID: sea-172538

ABSTRACT

Pyrexia with hepatosplenomegaly is a common problem in medical practice globally, specially in tropical countries. In Bangladesh several tropical diseases as well as hematological malignancies are responsible for such clinical syndrome. Again different tropical diseases vary in endemicity in different regions in Bangladesh. In Present study 50 hospitalized cases of pyrexia with hepatosplenomegaly of 15-50 years of age are included from 01.01.2002 to 30.06.2002 in MMCH to find out their aetiologies. Fever with only hepatomegaly, or with only splenomegaly or hepatosplenomegaly without fever was not included in this study. Duration of fever was two weeks to three months. 35(70%) cases were male and 15(30%) were female. 27(54%) cases were visceral leishmaniasis (kala-azar), 8 (16%) malaria, 6 (12%) Acute leukemia (ALL, AML), 3 (6%) Lymphoma, 3(6%) Enteric fever, 2(4%) CML, 1(2%) Disseminated TB. Although kala-azar and malaria are tow common causes of fever with hepatosplenomegaly, haematological malignancies and tuberculosis should be in mind.

SELECTION OF CITATIONS
SEARCH DETAIL